ALC.SW Alcon Inc. (SIX) ends CHF64.26 25 Feb 2026: heavy volume, earnings focus
The ALC.SW stock closed at CHF64.26 on 25 Feb 2026 with 1,407,710 shares traded, making it one of the most active names on the SIX today. Volume ran about 2.22x the average, signalling institutional attention ahead of the company’s next earnings date. Price action was contained between CHF64.00 and CHF65.42, while the stock sits -16.34% on the year and above its 50-day average of CHF62.82. Traders are watching margins and product mix after recent quarterly commentary.
Price action and market activity for ALC.SW stock
ALC.SW closed at CHF64.26 with a session range of CHF64.00–CHF65.42. Volume was 1,407,710, versus an average of 1,103,098, giving a relative volume of 2.22.
The share has a 1-year low of CHF57.68 and a 1-year high of CHF87.00. Year-to-date performance is +5.54% while the 1-year return is -16.34%, showing recent recovery but longer-term compression.
Fundamentals and valuation overview
Alcon reported trailing earnings per share of 1.62 and trades at a price-to-earnings ratio of 41.40, above healthcare peers. Book value per share is 44.74, giving a price-to-book near 1.94.
Key ratios show operating strength and moderate leverage: EV/EBITDA is 22.72, debt-to-equity is 0.24, and current ratio is 2.12. Free cash flow yield is about 3.70%, and dividend per share is 0.36 CHF with a payout ratio near 15.34%.
Catalysts, earnings calendar and recent news
Alcon’s next earnings announcement is scheduled for 05 May 2026, a date likely to move the high-volume trading seen today. Recent regional coverage flagged fourth-quarter results and margin pressure from increased investment and tariffs, which markets are parsing source.
Corporate conference calls and live earnings schedules keep traders nimble; Alcon appeared on investor call lists this week source. Investors are focused on surgical equipment sales, contact lens trends, and pricing mix ahead of the report.
Technical snapshot and trading signals
Momentum readings are constructive: RSI 68.65 and MACD histogram 0.64 suggest near-term strength without extreme overheating. Bollinger Bands sit at Upper 65.63 / Middle 62.07 / Lower 58.51, indicating the price is near the upper band.
Volume and momentum indicators show short-term buyer interest: Money Flow Index is 74.24 and CCI is 134.06, which often precede volatile moves around earnings.
Meyka AI grade and ALC.SW stock forecast
Meyka AI rates ALC.SW with a score out of 100: 74.97 (B+) — BUY. This grade factors in S&P 500 benchmark comparison, sector performance, financial growth, key metrics, and analyst consensus.
Meyka AI’s forecast model projects a monthly target of CHF57.30 and a yearly target of CHF61.27. Compared with the current price CHF64.26, the model implies a -4.61% downside to the yearly figure and -10.84% to the monthly figure. Forecasts are model-based projections and not guarantees.
Final Thoughts
ALC.SW stock traded as one of the most active Swiss listings on 25 Feb 2026, closing at CHF64.26 on volume 1,407,710. Fundamentals show a premium valuation with PE 41.40 and EV/EBITDA 22.72, balanced by solid cash flow yields and low leverage. Short-term technicals signal buyer interest but also overbought oscillators ahead of the 05 May 2026 earnings date. Meyka AI’s forecast model projects CHF61.27 for the year, implying a modest downside versus today’s price; that outlook underlines the market’s sensitivity to margin and revenue guidance. For traders, the stock’s high daily volume supports liquidity for tactical positions. For longer-term investors, a base-case price target near CHF66.00, a conservative target CHF58.00, and a bullish target CHF80.00 frame risk/reward. These figures and the Meyka grade are data-driven tools and not investment advice.
FAQs
What drove ALC.SW stock to be most active today?
Heavy trading was driven by elevated volume of 1,407,710 shares and pre-earnings positioning ahead of the 05 May 2026 results. News on margin compression and surgical product mix also drew attention.
How does Alcon’s valuation compare to peers?
Alcon trades at PE 41.40 and PB 1.94, above many healthcare names. EV/EBITDA of 22.72 suggests a premium for growth and proprietary surgical products.
What does Meyka AI forecast for ALC.SW stock?
Meyka AI’s forecast model projects CHF61.27 for the year and CHF57.30 for the month. These imply downside versus CHF64.26 and are model projections, not guarantees.
Disclaimer:
Stock markets involve risks. This content is for informational purposes only. Past performance does not guarantee future results. Meyka AI PTY LTD provides market analysis and data insights, not financial advice. Always conduct your own research and consider consulting a licensed financial advisor.